{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:30:37Z","timestamp":1787023837263,"version":"build-2736575974"},"reference-count":12,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,30]]},"DOI":"10.20945\/2359-3997000000408","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T17:30:09Z","timestamp":1633023009000},"source":"Crossref","is-referenced-by-count":4,"title":["Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism"],"prefix":"10.20945","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3933-6137","authenticated-orcid":false,"given":"Mohammad Shafi","family":"Kuchay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5902-4419","authenticated-orcid":false,"given":"Anu","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5642-2291","authenticated-orcid":false,"given":"Parjeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1759-1287","authenticated-orcid":false,"given":"Sunil Kumar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"issue":"21","key":"key20210930164754_B1","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.2217\/fon.15.232","article-title":"Denosumab: a new agent in the management of hypercalcemia of malignancy","volume":"11","author":"Thosani","year":"2015","unstructured":"1. Thosani S, Hu MI. Denosumab: a new agent in the management of hypercalcemia of malignancy. Future Oncol. 2015;11(21):2865-71.","journal-title":"Future Oncol"},{"issue":"5","key":"key20210930164754_B2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Leere","year":"2020","unstructured":"2. Leere JS, Karmisholt J, Robaczyk M, Lykkeboe S, Handberg A, Steinkohl E, et al. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2020;8(5):407-17.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"key20210930164754_B3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7861\/clinmedicine.17-3-270","article-title":"Hypercalcaemia \u2013 presentation and management","volume":"17","author":"Turner","year":"2017","unstructured":"3. Turner JJO. Hypercalcaemia \u2013 presentation and management. Clin Med (Lond). 2017;17(3):270-3.","journal-title":"Clin Med (Lond)"},{"issue":"2","key":"key20210930164754_B4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrendo.2017.104","article-title":"Primary hyperparathyroidism","volume":"14","author":"Walker","year":"2018","unstructured":"4. Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol. 2018;14(2):115-25.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"key20210930164754_B5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1210\/jc.2013-3031","article-title":"Denosumab for management of parathyroid carcinoma-mediated hypercalcemia","volume":"99","author":"Vellanki","year":"2014","unstructured":"5. Vellanki P, Lange K, Elaraj D, Kopp PA, El Muayed M. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia. J Clin Endocrinol Metab. 2014;99(2):387-90.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key20210930164754_B6","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4158\/EP14410.OR","article-title":"The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia","volume":"21","author":"Fountas","year":"2015","unstructured":"6. Fountas A, Andrikoula M, Giotaki Z, Limniati C, Tsakiridou E, Tigas S, et al. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia. Endocr Pract. 2015;21(5):468-73.","journal-title":"Endocr Pract"},{"issue":"12","key":"key20210930164754_B7","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1055\/a-1049-0647","article-title":"Diagnosis, pathophysiology and management of hypercalcemia in malignancy: a review of the literature","volume":"51","author":"Asonitis","year":"2019","unstructured":"7. Asonitis N, Angelousi A, Zafeiris C, Lambrou GI, Dontas I, Kassi E. Diagnosis, pathophysiology and management of hypercalcemia in malignancy: a review of the literature. Horm Metab Res. 2019;51(12):770-8.","journal-title":"Horm Metab Res"},{"key":"key20210930164754_B8","first-page":"41","article-title":"Denosumab as a bridge to surgery in patients with primary hyperparathyroidism, severe hypercalcemia and renal impairment","volume":"8","author":"Pugliese","year":"2016","unstructured":"8. Pugliese F, de Martino D, Scillitani A, Carnevalle V. Denosumab as a bridge to surgery in patients with primary hyperparathyroidism, severe hypercalcemia and renal impairment. Curr Trends Endocrinol. 2016;8:41-4.","journal-title":"Curr Trends Endocrinol"},{"issue":"2","key":"key20210930164754_B9","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.4158\/EP161270.CR","article-title":"Denosumab use for severe hypercalcemia in a man with end-stage renal disease on hemodialysis","volume":"3","author":"Manandhar","year":"2017","unstructured":"9. Manandhar S, Selk KL, Sobel SI. Denosumab use for severe hypercalcemia in a man with end-stage renal disease on hemodialysis. AACE Clin Case Rep. 2017;3(2):e116-20.","journal-title":"AACE Clin Case Rep"},{"issue":"2","key":"key20210930164754_B10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/ijem.IJEM_678_18","article-title":"Denosumab as a bridge to surgery in a patient with severe hypercalcemia due to primary hyperparathyroidism in the setting of renal dysfunction","volume":"23","author":"Rajan","year":"2019","unstructured":"10. Rajan R, Cherian KE, Kapoor N, Paul TV. Denosumab as a bridge to surgery in a patient with severe hypercalcemia due to primary hyperparathyroidism in the setting of renal dysfunction. Indian J Endocrinol Metab. 2019;23(2):269-70.","journal-title":"Indian J Endocrinol Metab"},{"issue":"4","key":"key20210930164754_B11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000510625","article-title":"Successful use of denosumab for life-threatening hypercalcemia in a paediatric patient with primary hyperparathyroidism","volume":"93","author":"Mamedova","year":"2020","unstructured":"11. Mamedova E, Kolodkina A, Vasilyev EV, Petrov V, Belaya Z, Tiulpakov A. Successful use of denosumab for life-threatening hypercalcemia in a paediatric patient with primary hyperparathyroidism. Horm Res Paediatr. 2020;93(4):272-8.","journal-title":"Horm Res Paediatr"},{"issue":"10","key":"key20210930164754_B12","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1530\/EC-20-0380","article-title":"Denosumab for management of severe hypercalcemia in primary hyperparathyroidism","volume":"9","author":"Eremkina","year":"2020","unstructured":"12. Eremkina A, Krupinova J, Dobreva E, Gorbacheva A, Bibik E, Samsonova M, et al. Denosumab for management of severe hypercalcemia in primary hyperparathyroidism. Endocr Connect. 2020;9(10):1019-27.","journal-title":"Endocr Connect"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T17:30:24Z","timestamp":1633023024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/denosumab-can-be-used-successfully-as-a-bridge-to-surgery-in-patients-with-severe-hypercalcemia-due-to-primary-hyperparathyroidism\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":12,"alternative-id":["10.20945\/2359-3997000000408"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000408","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]}}}